Adia Med Inc (ADIA) Fair Value & Analysis
Financial Services · US · Market cap $14.6M
Adia Med Inc
ADIA · US
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 48 days ago
Share price −25.0% over the past month.
Below-average quality, and screening another 83% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0200). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.0100 to $0.0200) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range $0.0010 – $0.2440 · fair‑value band $0.0100 – $0.0200 · the $0.1200 price screens above the $0.0200 fair value. Dashed = 300-day average. As of Jun 23, 2026.
Analysis
Adia Med Inc (ADIA) currently trades at $0.1200, while our model-based Fair Value estimate is $0.0200, implying the stock looks roughly 83.3% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Adia Med Inc generated revenue of $805K at a net margin of -54.9%. Revenue grew 145.6% year over year. Fundamentals as of Jun 23, 2026
Our scenario range runs from $0.0100 (bear case) to $0.0200 (bull case); at $0.1200, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at -83%, ADIA screens richer than that median.
Notify me when ADIA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Adia Med Inc offers medical treatments and nutritional supplements. The company operates in three segments: Biolete, Adia Med, and Adia Labs. It provides autologous hematopoietic stem cell transplantation (AHSCT) treatments for multiple sclerosis patients.
Full company description
Adia Med Inc offers medical treatments and nutritional supplements. The company operates in three segments: Biolete, Adia Med, and Adia Labs. It provides autologous hematopoietic stem cell transplantation (AHSCT) treatments for multiple sclerosis patients. The company also operates Adia Med, a clinic to perform stem cell treatments, and Adia Labs, which procures and sells stem cell products to outside clinics or Adia Med. In addition, the company offers nutritional supplements and biologic products. It sells its products on a direct-to-consumer basis, as well as through other direct to consumer channels. The company was formerly known as Adia Nutrition, Inc. and changed its name to Adia Med Inc in June 2026. Adia Med Inc is based in Winter Park, Florida.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2002 – FY2025 · reported fiscal years
Adia Med Inc reported revenue of $701K in FY2025 versus $415K in FY2002, a compound +2.3%/yr. Reported net income was −$395K in FY2025.
ADIA screens 83% overvalued. Compare with The Coca-Cola Company →
Peer Group
Shell Companies · 70 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$27.96 | C$10.91 | -61% |
| Lionheart III Corp LION | $13.47 | $18.15 | +35% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.45 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0320 | $0.0314 | -2% |
| GP-Act III Acquisition Corp GPAT | $10.91 | $4.30 | -61% |
| Berto Acquisition Corp TACO | $10.48 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.67 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.80 | $5.06 | -53% |
| Graf Global Corp GRAF | $10.82 | $3.63 | -66% |
Compare Adia Med Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Adia Med Inc (ADIA) overvalued or undervalued?
What is the fair value of ADIA?
What is the quality score of ADIA?
What is the revenue of Adia Med Inc (ADIA)?
What is the net profit margin of ADIA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Adia Med Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.